Literature DB >> 22440867

Pathology: commonly monitored glioblastoma markers: EFGR, EGFRvIII, PTEN, and MGMT.

Joaquin Q Camara-Quintana1, Ryan T Nitta, Gordon Li.   

Abstract

The purpose of this article is to update the neurosurgical field on current molecular markers important to glioblastoma biology, treatment, and prognosis. The highlighted biologic markers in this article include epidermal growth factor receptor (EGFR), EGFR variant III (EGFRvIII), phosphatase and tensin homolog deleted on chromosome 10 (PTEN), and O6-methylguanine-DNA methyltransferase (MGMT). Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22440867     DOI： 10.1016/j.nec.2012.01.011

Source DB:  PubMed          Journal:  Neurosurg Clin N Am        ISSN： 1042-3680            Impact factor:   2.509


  13 in total

Review 1.  Combining immunotherapy with radiation for the treatment of glioblastoma.

Authors:  Kevin K H Chow; Wendy Hara; Michael Lim; Gordon Li
Journal:  J Neurooncol       Date:  2015-04-17       Impact factor: 4.130

Review 2.  Glioblastoma antigen discovery--foundations for immunotherapy.

Authors:  Tej D Azad; Seyed-Mostafa Razavi; Benjamin Jin; Karen Lee; Gordon Li
Journal:  J Neurooncol       Date:  2015-06-05       Impact factor: 4.130

3.  Association of dynamic susceptibility contrast enhanced MR Perfusion parameters with prognosis in elderly patients with glioblastomas.

Authors:  Pejman Jabehdar Maralani; Elias R Melhem; Sumei Wang; Edward H Herskovits; Matthew R Voluck; Sang Joon Kim; Kim O Learned; Donald M O'Rourke; Suyash Mohan
Journal:  Eur Radiol       Date:  2015-02-14       Impact factor: 5.315

4.  OSU-03012 interacts with lapatinib to kill brain cancer cells.

Authors:  Laurence Booth; Nichola Cruickshanks; Thomas Ridder; Ching-Shih Chen; Steven Grant; Paul Dent
Journal:  Cancer Biol Ther       Date:  2012-09-18       Impact factor: 4.742

5.  Nimotuzumab in combination with radiotherapy in high grade glioma patients: a single institution experience.

Authors:  Maria Teresa Solomon; Nederlay Miranda; Eugenia Jorrín; Ivonne Chon; Jorge Juan Marinello; José Alert; Patricia Lorenzo-Luaces; Tania Crombet
Journal:  Cancer Biol Ther       Date:  2014-02-12       Impact factor: 4.742

Review 6.  Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science.

Authors:  Fred H Hochberg; Nadia A Atai; David Gonda; Michael S Hughes; Brolin Mawejje; Leonora Balaj; Robert S Carter
Journal:  Expert Rev Mol Diagn       Date:  2014-05       Impact factor: 5.225

7.  Aromatase and estrogen receptor alpha mRNA expression as prognostic biomarkers in patients with astrocytomas.

Authors:  J M Dueñas Jiménez; A Candanedo Arellano; A Santerre; S Orozco Suárez; H Sandoval Sánchez; I Feria Romero; R López-Elizalde; M Alonso Venegas; B Netel; B de la Torre Valdovinos; S H Dueñas Jiménez
Journal:  J Neurooncol       Date:  2014-07-09       Impact factor: 4.130

8.  Assessing current therapeutic approaches to decode potential resistance mechanisms in glioblastomas.

Authors:  Chun-I Sze; Wan-Pei Su; Ming-Fu Chiang; Chen-Yu Lu; Yu-An Chen; Nan-Shan Chang
Journal:  Front Oncol       Date:  2013-03-19       Impact factor: 6.244

9.  Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients.

Authors:  Shuwei Qiu; Sheng Lin; Dan Hu; Yimin Feng; Yang Tan; Ying Peng
Journal:  J Transl Med       Date:  2013-01-09       Impact factor: 5.531

10.  Combined PTEN Mutation and Protein Expression Associate with Overall and Disease-Free Survival of Glioblastoma Patients.

Authors:  Jie Xu; Zhaoli Li; Jilin Wang; Haoyan Chen; Jing-Yuan Fang
Journal:  Transl Oncol       Date:  2014-03-04       Impact factor: 4.243
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.